Introduction
Colorectal cancer is a tumor caused by abnormal division of the cells lining the large intestine. According to the American Cancer Society, there were an estimated 102,900 new cases and 51,370 deaths due to colorectal cancer in the United States in 2010. As such, there is a need for better treatment approaches for colorectal cancer. The cellular mechanisms contributing to colorectal cancer are still not well understood but involve signaling protein dysregulation which includes the constitutive activation of STAT3 (1) (2) (3) . The constitutive activation of STAT3 is frequently detected in primary human colorectal carcinoma cells and established human colorectal cancer cell lines (1) (2) (3) , and elevated levels of STAT3 phosphorylation were correlated with the tumor invasion, nodal metastasis, and the stage (P < 0.05; refs. 1, 3). Constitutive STAT3 activation in colorectal cancer cells is associated with invasion, survival, and growth of colorectal cancer cells and colorectal tumor model in mice in vivo (2, (4) (5) (6) . These reports indicate that STAT3 is one of the major oncogenic pathways activated in colorectal cancer and can serve as an attractive therapeutic target for colorectal carcinoma. To date, however, whether STAT3 is activated in colorectal cancer stem cells is unknown.
The concept of the cancer stem cells or cancer-initiating cells holds that only a minority of cells within a tumor have the ability to generate a new tumor. Cancer stem cells were reported to show pluripotency and self-renewal (7) . Cancer stem cells were first identified in leukemias and more recently in solid tumors. Increasing evidence suggests that the cancer stem cells concept is also relevant to colorectal cancer (8) . CD133, a transmembrane protein (Prominin-1 or AC133) was used to isolate stem cells from a host of other normal and cancerous tissues, including colorectal cancer. However, the specificity of CD133 alone as a marker for colonic stem cells is uncertain (9) (10) (11) .
A promising new marker for cancer stem cells is aldehyde dehydrogenase 1 (ALDH1). ALDH is a detoxifying enzyme that oxidizes intracellular aldehydes and thereby confers resistance to alkylating agents (12) . Corti and colleagues (13) showed that ALDH þ cells isolated from murine brain were capable of selfrenewal and of differentiating into multiple lineages. Further studies showed that ALDH1 is a specific marker for breast cancer stem cells (14, 15) . ALDH was also investigated as a specific marker for identifying and isolating normal and malignant human colonic stem cells and as a way to quantify the number of stem cells over the course of colon cancer development (16) . Xenograft tumors were successfully generated using ALDH þ cells from 7 primary colon cancer cells and ALDH À cells did not generate tumor xenografts (16) . When using ALDH and CD133 together to form tumor xenografts, ALDH þ /CD133 þ cells showed an increased ability to generate tumor xenografts compared with ALDH þ /CD133 À or ALDH þ alone (16) . Taken together, these data suggest that ALDH is a better marker than CD133 for colorectal cancer stem cells. However, using both ALDH and CD133 seem to be better than to enrich the cancer stem cell population using ALDH or CD133 alone. This study extends that work by using both ALDH and CD133 together as markers for cancer-initiating cells or colorectal stem cells and examines the STAT3 phosphorylation and interleukin 6 (IL)-6 expression in these cancer-initiating cells. Our results showed that colorectal cancer-initiating cells, characterized by ALDH þ /CD133 þ subpopulation of colorectal cancer cells expressing higher levels of STAT3 phosphorylation and IL-6, compared with unseparated and ALDH À /CD133 À subpopulations. These results suggest that STAT3 is a novel therapeutic target in colorectal cancer-initiating cells.
Materials and Methods

Colorectal cancer cell lines
Human colorectal cancer cell lines (SW480, HCT116, DLD-1, and HT29) were purchased from the American Type Culture Collection (ATCC) and maintained in Dulbecco's Modified Eagle Medium supplemented with 10% FBS (Invitrogen). These cancer cell lines have been routinely tested and authenticated by the ATCC and Asterand, respectively. The known genotype relative to adenomatous polyposis coli, beta-catenin, and DNA mismatch repair enzymes (MLH1, MSH2) genes were shown in Supplementary Table S1 . ALDH þ
/CD133
þ cancer-initiating cells were grown in a serum-free mammary epithelial basal medium (MEBM; Clonetics division of Cambrex BioScience), supplemented with B27 (Invitrogen), 20 ng/mL EGF (BD Biosciences), 4 mg/mL Gentamycin (Invitrogen), 1 ng/mL Hydrocortisone (Sigma-Aldrich), 5 mg/mL Insulin, and 100 mmol/L beta-mercaptoethanol (Sigma-Aldrich).
STAT3 inhibitors, LLL12, and Stattic
The laboratory of Dr. Pui-Kai Li's at the Ohio State University College of Pharmacy synthesized small-molecule LLL12 that selectively targets STAT3 (17) . Stattic, a previously reported STAT3 inhibitor (18) , was purchased from Calbiochem.
Isolation of colon cancer-initiating cells
The population with high ALDH enzymatic activity was isolated by using the ALDEFLUOR Kit (StemCell Technologies) as previously described (14) . Briefly, cells were trypsinized to single cells and subsequently suspended in ALDEFLUOR assay buffer containing ALDH substrate and then incubated for 40 minutes at 37 C. In all experiments, the ALDEFLUOR-stained cells treated with diethylaminobenzaldehyde, a specific ALDH inhibitor, served as ALDH-negative controls. Anti-human PE-CD133 antibody were purchased from Miltenyi Biotec. À and unseperated cells were cultured in regular medium and replaced with stem cell medium (MEBM) for 3 days before harvesting.
Tissue microarray slides, immunohistochemistry, and immunofluorescence staining Human colon cancer tissue microarray slides were obtained from the Biochain Institute, Inc. and AccuMax ISU ABXIS Co. containing 109 colon cancer cases. After baking and deparaffinization, the slides were boiled in a pressure cooker filled with 10 mmol/L sodium citrate (pH 6.0) and then subjected to immunohistochemistry or immunofluorescence staining. Phospho-STAT3 (Tyr705) antibody (1:25; Signaling Technology) and or ALDH1 (1:100; BD Pharmingen), CD133 (1:50; Miltenyi Biotec) were used. Alexa Fluor 488-conjugated anti-rabbit IgG and Alexa Fluor 594-conjugated anti-mouse IgG (Cell Signaling Technology) and the Histostain-Plus Kits (Invitrogen) were used in immunofluorescence or immunohistochemistry staining as described by the manufacturer. Immunostained slides were scored under microscope by using the criteria of percentage and intensity positive as described previously by Ginestier (14) . Significance of correlation between phospho-STAT3 and ALDH1 or CD133 was determined, respectively, using 2-sided Pearson x 2 test. P < 0.05 was considered as statistical significance.
Cell viability assay
Colon cancer-initiating cells maintained serum-free MEBM (3,000 per well in 96-well plates) were incubated with desired concentrations of compounds in triplicate at 37 C for 72 hours. MTT viability assay was done according to manufacturer's protocol (Roche Diagnostics). The absorbance was read at 595 nm.
Western blot analysis
Cells were lysed in cold radioimmunoprecipitation assay lysis buffer containing protease inhibitors and subjected to SDS-PAGE. Proteins were transferred on to polyvinylidene difluoride membrane and were probed with a 1:1,000 dilution of antibodies (Cell Signaling Technology) against phosphospecific STAT3 (Tyrosine 705; P-STAT3), phospho-independent STAT3, phospho-specific ERK1/2 (Threonine 202/Tyrosine 204), cleaved PARP, cleaved caspase-3, cyclin D, survivin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The degree of changes in P-STAT3 was determined using densitometry and normalized to GAPDH.
Reverse transcriptase PCR
Total cell RNA was collected from cells by using RNeasy Kits (Qiagen). cDNA was generated from 500 ng sample RNA using Omniscript RT (Qiagen). Two microliter of cDNA was subsequently used for PCR using Taq PCR Master Mix Kit (Qiagen) according to the manufacturer's instruction. Primer sequences and source information can be found in Supplementary  Table S2 .
Tumorsphere culture
The ALDH þ /CD133 þ cells was plated as single cells in ultralow attachment 6-well plates (Corning) and plated at a density of 25,000 viable cells per well. Cells were grown in a serum-free MEBM as described above in a humidified incubator (5% CO 2 ) at 37 C. At the second day after seeding, the ALDH þ /CD133 þ cells were treated with 2.5 to 5 mmol/L of LLL12 or 5 to 10 mmol/L of Stattic. Tumorspheres were observed under microscope 15 days later.
IL-6 ELISA assay
were cultured in 96-well plates at a density of 12,000 viable cells per well. Twenty-four hours later, the medium was collected and the IL-6 concentrations were detected by using the Human IL-6 ELISA Development Kit (Peprotech) as described by the manufacturer.
Lentiviral infections
Lentivirus short hairpin RNA (shRNA) that specifically targets human STAT3 (19) and control lentivirus that expresses green fluorescent protein (GFP) were provided by Dr. Antonio Iavarone at the Columbia University. IL-6 shRNA lentivirus was purchased from Santa Cruz Biotechnology, Inc. STAT3, IL-6, or control GFP shRNA lentivirus (CTL shRNA) was introduced into SW480 and HCT116 colon cancer-initiating cells for 48 hours, followed by selection with puromycin (0.2 mg/mL) for 72 hours. Western blot assay was used to detect the expression of P-STAT3 and STAT3 in colon cancer-initiating cells. MTT cell viability and reverse transcriptase PCR (RT-PCR) assay were conducted and in vivo cancer-initiating cell growth was determined.
Mouse xenograft tumor model
All animal studies were conducted in accordance with the principles and standard procedures approved by IACUC at the Research Institute at Nationwide Children's Hospital. For tumor-initiation study, the ALDH
, or 1 Â 10 4 ) from SW480, HCT116, DLD-1, and HT29 were mixed with 50% Matrigel (Invitrogen) in a total of 100 mL and were injected subcutaneously into the right flank area of 4-to 5-week-old female nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, which were purchased from Jackson Laboratory. The tumor incidence ALDH were mixed with 50% Matrigel (Invitrogen) in a total of 100 mL and were injected subcutaneously into the flank area of female NOD/SCID mice. After 17 and 19 days, SW480 and HCT116 mice were divided into 2 treatment groups consisting of 5 and 6 mice per group, respectively: (a) dimethyl sulfoxide (DMSO) control vehicle and (b) 5 mg/kg of LLL12 (dissolved in 10% DMSO, 18% Cremophor EL and 72% sterile 5% dextrose). Tumor growth and body weights of mice were measured every other day during 14 days period treatments. At the end of treatments, tumors were harvested from euthanized mice. A portion of tumor tissues was snap-frozen in liquid nitrogen and stored in À80
C to examine the expression of STAT3 phosphorylation by Western blot. The rest of tumors tissues were dissociated mechanically and enzymatically to obtain a single-cell suspension. The single-cell suspension was used for ALDEFLUOR and CD133-PE staining and followed flow cytometry assay as previously described (20) .
Results
LLL12 is a potent agent to inhibit the STAT3 phosphorylation in colorectal cancer cells
STAT3 is frequently activated in many types of human solid and blood cancers and contributes to progression of those cancers (21, 22) . The STAT3 pathway is also frequently constitutively activated in colorectal cancer and is considered to play an important role in colorectal cancer carcinogenesis (1) (2) (3) (4) (5) (6) . To confirm the important role of STAT3 in colon cancer cells, the novel STAT3 inhibitor LLL12 (17) was used to target STAT3 in 3 independent colon cancer cell lines using phosphospecific STAT3 antibody. Our results showed that LLL12 significantly inhibited STAT3 phosphorylation at tyrosine residue 705 (Y705, P-STAT3) in SW480, HCT116, and DLD-1 human colon cancer cell lines ( Supplementary Fig. S1 ). Phosphorylation at Y705 is important to activate STAT3 (23) (24) (25) . The inhibition of P-STAT3 by LLL12 is consistent with the decrease of STAT3 downstream target genes and the induction of apoptosis, as evidenced by the cleavages of caspase-3 ( Supplementary Fig. S1 ). To further investigate the STAT3 activation in clinical colon cancer samples, P-STAT3 and ALDH1, CD133 protein expression in human colon cancer tissues were also examined using tissue microarray slides. We observed that there was a significant association (P < 0.01) between staining of P-STAT3 and staining of ALDH1 (Table 2 ). In addition, the tumor samples expressed elevated levels of phosphorylated STAT3 also associated with CD133 (P < 0.01; Table 2 ). In the 109 cases, there were 32 samples (29.36%) in which P-STAT3 (Y705), ALDH1, and CD133 were all positive, and 38 samples (34.86%) with negative P-STAT3 (Y705), ALDH1, and CD133. Taken together, there were 64.22% samples which had the similar expression, much more than the samples with different expression of these 3 proteins (P < 0.05; Table 2 ). So there was a significant association between P-STAT3, ALDH1 and CD133. The representative examples of immunohistochemistry/immunofluorescence staining of P-STAT3 and ALDH1/CD133 are shown in Fig. 1B and C. These results from human colon cancer tissue further showed that the elevated levels of P-STAT3 is expressed in colon cancer-initiating cells. These results indicated that constitutive STAT3 signaling may be a novel therapeutic target in colorectal cancer-initiating cells. In Fig. 2B , Stattic seems to decrease STAT3 expression, which could explain, in part, the observed decrease in level of P-STAT3. In addition, STAT3 shRNA also inhibited P-STAT3 in ALDH þ /CD133 þ subpopulation of colorectal cancer cell lines compared with shRNA control (shRNA CTL; Fig. 2C ). The inhibition of STAT3 by LLL12 also downregulates the expression of many known or putative STAT3-regulated genes in colorectal cancer-initiating cells such as cyclin D1 (26) , survivin (27) , Bcl-2, Bcl-XL (26), Notch1, and Notch3 (28, 29; Fig. 2D-a, Supplementary Fig. S4C ). These genes are related to cancer cell proliferation, survival, and angiogenesis. Moreover, the Notch pathway was reported to be involved in self-renewal of human cancer stem cells and tumorigenicity (28, 30) . These results indicate that the LLL12 is also potent in terms of inhibiting P-STAT3, downregulating STAT3 downstream genes, and induces apoptosis in these colorectal cancer-initiating cells. Furthermore, the expression of STAT3 downstream genes, such as cyclin D1, survivin, Bcl-XL, Notch1, and Notch3 were also reduced by STAT3 shRNA (Fig. 2D-b) . Fig. 4C-a) as detected by RT-PCR assay. We also examined the ALDH1 and CD133 expression after the LLL12 treatment. We found that the expression of ALDH1 and CD133 was lower after treatment with LLL12 ( Fig. 4C-b) . In addition, LLL12 inhibited the expression of IL-6, GP130, and IL-8 ( Fig.  4C-b) . However, the expression of IL-6R was not changed consistently in all 4 cell lines. Our data also observed that IL-6 (25-50 ng/mL) induced the expression of IL-8 in SW480 and HCT116 colon cancer cells, which could be blocked by LLL12 ( Supplementary Fig. S6C ). The results confirm that the IL-6/STAT3 pathway plays a central role in the maintenance of the ALDH þ /CD133 þ subpopulation in colon cancer cells.
IL-6 shRNA decreased STAT3 phosphorylation of colorectal cancer-initiating cells in vitro and inhibited cancer-initiating cell growth in vivo
To determine whether the increased levels of phosphorylated or activated STAT3 in ALDH þ /CD133 þ cells is dependent on upstream ligand, IL6, we treated ALDH þ /CD133 þ cells with lentiviral IL-6 shRNA versus control lentivirus without encoding IL-6 shRNA. Our results in Fig. 4D -a shows that lentiviral IL-6 shRNA, but not control lentivirus, downregulated the phosphorylated STAT3. These results provide evidence that elevated levels of phosphorylated STAT3 in ALDH þ /CD133 þ cells is IL-6-dependent and the inhibition of IL-6 downregulates phosphorylated STAT3. To further show the tumor dependence on STAT3 and its upstream activation (IL-6), we used shRNA that specifically knock down STAT3 and its upstream signaling protein, IL-6. Our results in Fig. 4D-b shows that STAT3 and IL-6 shRNA significantly suppressed colon cancer stem cell tumor growth compared with lentivirus GFP (as a control). These data supported tumor dependence on STAT3 and its upstream activation by IL-6.
LLL12 suppresses tumor growth of colorectal cancerinitiating cells in mouse tumor model in vivo
We have shown that LLL12 inhibited P-STAT3, cell viability, and tumorsphere growth in colorectal cancer-initiating cells expressing elevated levels of STAT3 phosphorylation in vitro.
We further tested LLL12 against colorectal cancer-initiating cells isolated from the SW480 and HCT116 colon cancer cells in NOD/SCID mice xenograft model in vivo. The results showed that LLL12 significantly suppresses (P < 0.01) the tumor growth ( Fig. 5A-a) and tumor mass (Fig. 5A-b) . The average reduction in tumor weight is 49.67% to 61.89% in LLL12-treated mice compared with DMSO vehicle in xenograft mouse model (Fig. 5B ). LLL12 also inhibited STAT3 but not ERK1/2 phosphorylation of SW480 and HCT116 colon cancer-initiating cells (Fig. 5C ). We also used flow cytometry to determine the percentage of ALDH1 subpopulation in tumor. In addition, the body weights of mice have no obvious reduction in both DMSO vehicle-and LLL12-treated mice (Supplementary Fig. S7 ). These results showed that LLL12 is potent in suppressing tumor growth from the colorectal cancer-initiating cells in vivo.
Discussion
STAT3 is frequently activated in many types of human solid and blood cancers, including colon cancer (1-3, 22) .
Blocking signaling to STAT3 inhibits cancer cell growth, showing that STAT3 is crucial to the survival and growth of tumor cells (21, 22, 32) and is an attractive therapeutic target for cancer. At the present time, the main effort to target constitutive STAT3 signaling is only focused on the bulk of cancer cells. No published literatures have been reported about whether STAT3 is activated in colon cancer-initiating cells, and no approach has been initiated to explore the STAT3 as a possible therapeutic target in colon cancerinitiating cells. In this article, we took a pilot study to explore indeed a novel therapeutic target in colon cancer-initiating cells.
To explore the role thatSTAT3 plays in colon cancerinitiating cells, we examined the effects of STAT3 inhibition. Two small molecular STAT3 inhibitors, LLL12 (17) and Stattic (18) were employed. LLL12 is a novel and more potent derivative of LLL3, a previously reported STAT3 inhibitor from our laboratories (33, 34) . Our results showed that LLL12 was potent inhibitor to inhibit P-STAT3; STAT3 downstream targets expression and induces apoptosis in nonseparated colon cancer cells. Importantly, STAT3 inhibitors, LLL12 and Stattic inhibited P-STAT3, STAT3 downstream gene expression, cell viability, and the formation of tumorspheres in ALDH þ /CD133 þ subpopulation of colon cancer-initiating cells. In addition, STAT3 shRNA was used to inhibit the STAT3 expression and activity. Our results showed that STAT3 shRNA also inhibited STAT3 phosphorylation, cell viability, and STAT3 downstream genes (15) , which imply that inflammatory microenvironment is important in promoting the oncogenesis. Ginestier and colleagues reported that blockade of the IL-8 receptor CXCR1 selectively depletes human breast cancer stem cells (40) . Our data suggested that IL-6/STAT3/IL-8 activation in colon cancer-initiating cells might play an important role in the development of colon cancer.
We found that the expression of ALDH1 and CD133 was reduced after treatment with LLL12, and this may be due to the inhibition of their expression. It may also be an effect of LLL12 on cellular heterogeneity, whereby it decreases the proportion of ALDH þ /CD133 þ cells in the tumor cell population which was shown by our in vitro and in vivo data. In addition, our data showed that STAT3 inhibitors, but not other cancer therapeutic drugs such as doxorubicin and 5-Fu, eliminated ALDH þ /CD133 þ subpopulation of colon cancer-initiating cells in colon cancer cell lines. These results suggested that colon cancer-initiating cells, which are more resistant to conventional drugs, might be sensitive to STAT3 inhibitors. Furthermore, our results showed that STAT3, IL-6 shRNA and LLL12 exhibited suppressive activity on the tumor growth of human colon cancer-initiating cells derived from bulk colon cancer cells. These results suggest that constitutive active IL-6/STAT3 in these cancer-initiating cells enhanced proliferation and survival, as well as tumor growth in mice, whereas STAT3 blockade by STAT3, IL-6 shRNA and LLL12, suppressed tumor-initiating cell growth in vivo.
In summary, this study is the first report to show that IL-6/STAT3 is activated in colon cancer-initiating cells. Targeting IL-6/STAT3 may be able to eliminate the colon cancer-initiating cells and provides a promising approach to treat advanced colon cancer. Our study also showed that LLL12 is a potent STAT3 inhibitor for cancer-initiating cells and is a promising drug candidate to target constitutive STAT3 signaling in colon cancer-initiating cells. Most recently, 2 literatures reported that IL-6/STAT3 pathway may be activated in glioblastoma stem cells (41, 42) . In addition, targeting STAT3 by 2 small molecules, STA-21 and S31-201 or IL-6 shRNAs, respectively, can inhibit cell viability of these glioblastoma stem cells (41, 42) . Furthermore, we also observed that high levels of STAT3 phosphorylation are detected in breast cancer-initiating cells compared with unseparated and nonbreast cancer-initiating cells (data not shown). These results are consistent with our observation in colon cancer-initiating cells that activated STAT3 seems to play an important role in cancer-initiating cells. It is also of interest to investigate whether STAT3 is also activated in cancer-initiating cells in other types of human cancer. If STAT3 is constitutively activated in other types of cancerinitiating cells or cancer stem cells, it may open a new therapeutic opportunity to target STAT3 in cancer-initiating cells of those cancer types.
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